Cancer patients are more likely to take part in clinical trials that use decentralized technologies, according to analysis by U.S. researchers.
The survey, conducted by American Cancer Society Cancer Action Network (ACS/CAN) researchers, looked at the impact “decentralization tools”—wearable and self-report systems, online portals, etc.—have on patient participation in drug trials.
